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Summary The enzyme thymidine kinase is associated with DNA synthesis. Thymidine kinase serum levels
were studied in normal controls (n = 20), patients with primary breast cancer (n = 60), patients with systemic
breast cancer (n = 20) and as a non-cancer disease control group in patients with inflammatory gastrointes-
tinal disorders (n = 20). Comparison of pretreatment values in the cancer patients with the normal controls
showed a significant difference between the three groups in relation to stage of disease: mean values 4.22
(± 1.08), 6.22 (± 2.24) and 9.79 (± 7.56) pmol ml- 'h-' for normal controls, operable breast cancer and
systemic breast cancer respectively (P <0.005; analysis of variance). Patients with systemic breast cancer had a
significantly elevated serum thymidine kinase level compared to controls (P <0.01) and patients with primary
operable cancer (P <0.05). Patients with primary operable cancer had significantly higher serum thymidine
kinase levels over normal controls (P <0.01). Mean serum TK in patients with inflammatory gastrointestinal
diseases was similar to normal controls but significantly less than both patients with primary operable breast
cancer and patients with systemic breast cancer. Twenty patients with operable breast cancer were followed up
after primary surgery by serial 3-monthly thymidine kinase levels in the disease free interval. Four patients
have developed systemic recurrence with a rise in the mean thymidine kinase value to 14.3 pmol ml-l h'-. Ten
patients with advanced breast cancer had serial thymidine kinase levels measured 2-monthly during the first 6
months of primary hormone therapy. The serum values fell in all five responders (mean
9.12-4.78 pmol ml -' h-') and rose in all five progressors (mean 8.62-38.5 pmol ml I h '). Serum thymidine
kinase reflects stage of disease in breast cancer. Serial thymidine kinase levels in patients with systemic breast
cancer reflected response to systemic therapy.
Thymidine kinase (TK) is a pyrimidine nucleotide salvage
pathway enzyme with two isoenzyme forms, cytosolar TK
(TK1) and mitochondrial TK (TK2). The former has been
reported to be associated with dividing cells (Bello, 1974)
while activity of TK2 has been reported to remain constant
throughout the cell cycle (Adler & McAuslan, 1974).
Thymidine kinase is known to be involved in DNA replica-
tion with high TK activity reported in rapidly proliferating
tissues (Taylor et al., 1972; Nawata & Kamiya, 1975;
Sakamoto et al., 1984, 1985).
Serum TK has been reported to be elevated in a number of
malignant conditions (Kreis et al., 1982; O'Neill et al., 1986,
1987; Ellims et al., 1981; Eriksson et al., 1985), including
breast cancer (McKenna et al., 1988). This study examined
pretreatment serum TK levels both in patients with primary
operable breast cancer and in patients with systemic breast
cancer.
Serial TK measurements were carried out in patients with
operable breast cancer to assess its usefulness in detecting
recurrence in the disease-free interval. The usefulness of serial
TK measurements as a measure of response to endocrine
therapy in patients with systemic breast cancer was also
investigated. The relative contributions of TKI and TK2
isoenzymes to any increases in serum total TK levels was
assessed.
Patients and methods
Serum TK levels were measured from stored serum in 20
control women with no evidence of breast disease, in 60
patients with operable primary breast cancer and in 20
patients with systemic breast cancer. The mean age of
patients in each group is shown in Table I. Patients with
systemic disease were significantly older than normal controls
(P <0.02) and patients with operable disease (P <0.01).
Previous studies have shown no effect of age on serum total
TK (McKenna et al., 1988). However, age-matched sub-
groups of the controls, operable and systemic breast cancer
patients were analysed for serum total TK (Table II).
The 20 control patients were divided into two groups: ten
patients were attending hospital with benign conditions for
minor surgical procedures and had no breast abnormality on
routine clinical examination; the other ten women, drawn
from the Nottingham breast screening programme, had
mammographically normal breasts and no previous history
of breast disease. Serum was taken from all patients attend-
ing hospital for surgery before operation.
The 60 patients with operable breast cancer were equally
divided into three prognostic groups (good, moderate and
poor) based on the Nottingham prognostic index (Todd et
al., 1987), with annual mortality rates of 3%, 7% and 30%
respectively. These 60 patients were selected from a group of
100 consecutive patients who presented with primary
operable breast cancer and from whom pretreatment blood
samples were obtained. By the Nottingham prognostic index
29 patients fell into the good prognostic group, 50 patients
were in the moderate group and 21 in the poor prognostic
group. One patient in the poor prognostic group was diag-
nosed as having liver metastases within 1 month of primary
surgery. The remaining 20 patients in the poor prognostic
group were matched with the first 20 patients in the good
prognostic group and the first 20 patients in the moderate
prognostic group. No patient received systemic adjuvant
therapy.
Patients in the poor prognostic group have a high rate of
recurrence. To evaluate TK as a serum marker of recurrence,
patients in the poor prognostic group were followed up at
3-monthly intervals by clinical and radiological examinations,
haematological and biochemical tests and serum TK levels.
The mean duration of follow-up was 7.5 months.
The 20 patients with systemic breast cancer had serum TK
levels measured before systemic therapy. All patients were
initially treated with hormone therapy. Ten of these patients
(five responders and five progressors) had serial serum TK
levels measured at 0, 2, 4 and 6 months during hormone
therapy to assess whether serum TK either predicted or
measured response to endocrine therapy. All patients
received the anti-oestrogen drug tamoxifen. One
premenopausal patient received the LHRH agonist Zoladex
(which produces castrate levels of oestradiol and pro-
gesterone) in combination with tamoxifen.
Patients with inflammatory gastrointestinal disease were
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Table I Serum TK levels
Pre-treatment Mean %
Number of Mean age mean total CTP/ATP
Patient group patients (± s.d.) serum TK TK activity
Controls 20 49.55 (± 12.05) 4.22 (± 1.08) 72.7 (± 37.3)
Operable 60 50.93 (± 10.25) 6.22 (± 2.24) 62.0 (± 20.9)
breast cancer
Good 20 49.50 (± 10.89) 6.32 (± 2.48) 56.8 (± 21.7)
prognosis
Moderate 20 50.90 (± 10.01) 6.21 (± 1.88) 56.4 (± 15.6)
prognosis
Poor prognosis 20 52.40 ( 10.15) 5.95 ( 2.40) 69.0 ( 23.1)
Systemic 20 59.55 (± 12.14) 9.79 (± 7.56) 62.7 (± 44.6)
breast cancer
Analysis of variance P <0.005 P=0.39
Table II Serum TK levels in age matched subgroups
Mean
Mean total serum
n age (years) TK ( s.d.)
Controls 10 57.4 3.87 (± 0.95)
Operable 30 57.1 6.27 (± 2.17)
breast cancer
Systemic 10 56.8 7.92 (± 4.07)
breast cancer
Analysis of variance P = 0.9611 P <0.003
chosen as a non-cancer disease control group since these
patients might be expected to have increased.cell proliferation
and possibly as a result an elevated serum TK. Of the 20
patients in this group 11 had colitis, six had Crohn's disease,
one had acute cholecystitis, one had acute pancreatitis and
one had acute appendicitis.
In all patients peripheral venous blood was obtained, cen-
trifuged and serum pipetted off. Serum was stored initially at
- 20°C and then at - 70C. TK is highly stable in serum
stored at - 20°C (Gronowitz et al., 1984).
Full details of the TK enzyme assay have been previously
published (O'Neill et al., 1986). In brief the TK assay mix
consisted of 0.02 M Tris (pH 7.8), 2 x 10-6 M 3H-thymidine
(85 Ci mmol-'), 0.002 M MgCl2, 0.2 M KCI, 0.1 M NH4CI,
0.005 M mercaptoethanol and 0.004 M ATP. The assay mix
also contained 0.5 mg ml-.' bovine serum albumin. Tubes
containing equal quantities of assay mix and serum to a total
volume of 200 LI were incubated for 60 min at 37°C before
spotting (25 pLI) on Whatman diethylaminoethyl (DEAE) cel-
lulose (DE-81) paper discs. The discs were subsequently
washed three times (3 x 5 min) in 0.001 M ammonium for-
mate (1Oml per disc), washed in distilled water and fixed in
absolute ethanol. The dried discs were placed in glass scintil-
lation vials and counted in 5 ml toluene based scintillant
containing Triton X-100.
A second assay mix was prepared containing cytidine
triphosphate (CTP) instead of ATP as phosphate donor. The
substitution of CTP results in a relative decrease in activity
of between 85 and 90% for TK1 and between 7 and 30% for
TK2. This was used to measure the relative contributions of
the TKI and TK2 isozymes to total TK activity (Ellims et
al., 1981).
All serum samples were measured for TK within the same
assay batch except for the gastrointestinal disease samples
which were measured in a second assay batch. All samples
were measured in quadruplicate and the mean value cal-
culated. The intra-assay variability for TK in this study was
5%. The inter-assay coefficient of variation was 8%.
All serum TK results quoted are in pmol ml1 h-' and are
total TK values unless stated. All serum TK measurements
were carried out without any knowledge of clinical inform-
ation.
Assessment ofresponse
Clinical Assessment of clinical response in patients with
systemic disease was by UICC criteria (Hayward et al.,
1977), adhering to the British Breast Group recommendation
that the minimum duration of remission be 6 months (British
Breast Group, 1974). External review of response was
obtained in all patients.
Biochemical Response to therapy in patients with systemic
breast cancer is assessed in the same manner for all serum
markers studied in this unit. A cut-off level for each indivi-
dual marker of the mean+ 2 s.d. of the normal control
group is calculated. Patients who never show an elevation of
the marker above this level are regarded as biochemically
unassessable for that particular marker. Patients with an
initial pretreatment value below the cut-off level which subse-
quently rises above the cut-off level or patients with an initial
value above the cut-off level which subsequently increases
above the interassay coefficient of variation for that partic-
ular marker, are regarded as showing increasing marker
levels indicative of 'biochemical progression'. Patients who
start with initially elevated values which fall either by greater
than the coefficient of variation or fall to below the cut-off
level are regarded as showing decreasing marker levels
indicative of 'biochemical response'. Patients with levels
which start and remain above the cut-off but which move
<± 10% of the baseline value are regarded as 'bio-
chemically stable'. This assessment of biochemical response
has been applied in interpreting the TK results in the 10
systemic breast cancer patients receiving hormone therapy.
Results
Serum TK levels were elevated in patients with breast cancer
compared to normal controls (Table I) (P<0.005; analysis
of variance). The highest levels were found in patients with
systemic breast cancer which as a group were significantly
higher than both the normal controls (P <0.01) and the
operable breast cancer patients (P <0.05). However, serum
TK in patients with operable breast cancer was also
significantly higher than in normal controls (P <0.01).
Analysis of age matched subgroups showed that serum total
TK levels were still elevated in patients with breast cancer
(P <0.003; analysis of variance) (Table II).
The mean serum TK in patients with inflammatory gastro-
intestinal diseases was 4.83 (± 1.73) pmol ml-' h-' with
mean % CTP/ATP activity of 58.6 (± 16.8). Serum TK in
this group of patients was similar to normal controls
(P = 0.2) but significantly less than with patients with
primary operable breast cancer (P = 0.01) and patients with
systemic breast cancer (P = 0.01).
The mean (± s.d.) for the 60 patients with operable breast
cancer was 6.22 (± 2.24). The pre-surgery serum TK value of
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analysed and found to be 6.32 (± 2.48), 6.21 (± 1.88) and
5.95 (± 2.40) respectively (Table I): there was no significant
difference between any of the three groups.
Twenty patients with operable breast cancer but in the
poor prognostic group according to the Nottingham index
have been followed up after surgery with 3-monthly serial
serum TK levels during the disease free interval. Four
patients have developed systemic recurrence, three local
recurrence and 13 were disease-free when last seen; one of
these 13 patients developed a contralateral primary car-
cinoma during the disease-free interval, had a mastectomy
and is currently disease-free. The mean pre-surgery serum
TK levels for the groups with systemic, local and no recur-
rence were 5.8 (± 2.7), 7.4 (± 1.6) and 5.6 (± 2.4) respec-
tively; for the three groups the corresponding mean values
were at systemic recurrence 14.3 (± 12.2), at local recurrence
5.4 (± 0.3) and at the last disease-free assessment 5.3 (± 1.5).
Pre-surgery serum TK values were similar between patients
who have developed early recurrence and those who have
not. There was no rise in serum TK in any of the patients
with local recurrence. A rise was seen in three of the four
patients who developed systemic recurrence (Table III). In
the remaining patient serum TK at diagnosis and at systemic
recurrence was below the cut-off level.
The mean pre-treatment serum TK value for the 20
patients with advanced disease was 9.79 (± 7.56). The mean
pre-treatment serum TK values for the five patients who
responded and the five patients who progressed on endocrine
therapy were 9.1 (± 4.7) and 8.6 (± 3.5) respectively.
On serial measurement serum TK fell in all five responders
to a mean value of 4.7 (± 0.96) at 6 months on therapy and
rose in the five progressers to a mean value of 38.5 (± 52.2).
Serum TK before and after treatment relative to the cut-off
level (mean + 2 s.d. of normal control group) in these five
responders and five progressors are shown in Tables IV and V
respectively. Changes in serum TK as a percentage of the
pretreatment TK is also shown in Tables IV and V. In four of
the five responders serum TK values moved from above the
cut-off level pretreatment to below the cut-off level indicative
of response by our assessment criteria: decrease in serum TK
of63%, 56%, 43% and 25% were well above the coefficient of
variation (Table IV). In the remaining patient serum TK
remained below the cut-off level throughout treatment. In four
of the five progressors serum TK started above the cut-off
level and increased by 907%, 178%, 155% and 70%,
indicative of progression (Table V). In the remaining patient
serum TK started and finished above the cut-off level with a
change of + 1% representing 'biochemically stable' disease.
By measuring the % CTP/ATP TK activity it is possible to
assess whether any increase in serum TK activity is due
mainly to an increase in TK1, TK2 or a combination of
both. The pre-treatment mean % CTP/ATP TK activity for
patients in the normal controls, operable disease and systemic
disease groups are shown in Table I.
The patterns of serum TKI and TK2 were analysed in
patients who had serial serum TK measurements and found
to be similar between the patients in the poor prognostic
group who developed recurrence on follow-up and those who
did not. The pattern of TK1 and TK2 was also similar in the
groups of patients with systemic disease who responded and
who progressed. In all the groups elevation of serum TK
Table IV Changes in serum TK in five patients with systemic breast
cancer with a minimum duration of response of 6 months
Pre-treatment TK TK at 6 months response
Relative to mean TK Relative to mean
+2s.d. of the TK+2s.d. of
normal control normal control
Patient group group % change
BH Above Below - 63
VM Above Below - 56
EW Above Below -43
AP Above Below - 25
DS Below Below - 17
Mean TK + 2 s.d. of normal control group = 6.4 pmol ml-' h-'.
Table V Changes in serum TK in five patients with systemic breast
cancer which progressed within 6 months of therapy
Pre-treatment TK TK at progression
Relative to mean TK Relative to mean
+2s.d. of the TK+2s.d. of
normal control normal control
Patient group group % change
BM Above Above 907 increase
ER Above Above 178 increase
MT Below Above 155 increase
EP Above Above 70 increase
ES Above Above I increase
Mean TK + 2 s.d. of normal control group = 6.4 pmol ml- h-'.
activity would appear to be due to an increase in both
isoenzymes with TK1 generally showing a greater increase in
activity.
It is noteworthy that the % CTP/ATP TK activity was
lower in this study than in previous studies (O'Neill et al., 1987; McKenna et al., 1988). This was due to the level of
ATP being increased in the assay mix from 0.002 to 0.004 M
as a result of enzyme kinetic studies to determine the
optimum levels of ATP for maximum efficiency of the TKI
isoenzyme (McKenna et al., unpublished observation).
Discussion
Serum TK has been reported to be elevated in a number of
malignancies (Kreis et al., 1982; O'Neill et al., 1986, 1987; Ellims et al., 1981; Eriksson et al., 1985; McKenna et al., 1988). This study shows that TK is significantly elevated in
the serum of breast cancer patients when compared both to
normal controls and to patients with inflammatory gastro-
intestinal diseases.
Serum TK levels are significantly higher in patients with
systemic disease compared to patients with operable primary
breast cancer (Table I), both being elevated over normal
controls. The age of patients with systemic disease was
significantly older than normal controls and patients with
operable disease: the increased age might be expected as
patients may develop systemic disease up to 30 years after
initial surgery for an operable primary lesion. We believe that
Table III Percentage changes in serum TK compared to pretreatment TK during the disease free
interval in four patients who developed systemic recurrence
Pre-treatment TK Post-surgery At diagnosis of metastases
Above or below Above or below
mean + 2s.d. of mean + 2s.d.
Patient normal controls (% change) normal control % change
JC Above -1 Above 233 increase
MT Below + 89 Above 187 increase
GL Below - 40 Above 25 increase
JP Below + 122 Below 49 increase
Mean TK + 2 s.d. or normal control group = 6.4 pmol ml-' h-'.666 J.F.R. ROBERTSON et al.
age was not a factor in the increased serum TK levels in
patients with systemic breast cancer: serum TK levels were
significantly higher in patients with operable disease com-
pared to normal controls although age in both groups was
similar. In addition analysis of age matched subgroups of the
controls, operable and advanced breast cancer patients
showed that serum TK was still elevated for stage of disease
(Table II). This confirms previous work showing no age
effect on serum TK levels (McKenna et al., 1988).
Serum TK has been shown to be elevated in a number of
other malignancies. We have tried to examine whether eleva-
tion of serum TK is also found in non-cancerous conditions
as a reflection of increased cell turnover/proliferation such as
might be expected with acute inflammatory gastrointestinal
diseases. The mean serum TK in the group of patients with
inflammatory gastrointestinal diseases was similar to that in
normal controls, and like the normal controls was
significantly less than patients with primary operable breast
cancer and systemic breast cancer. Further work investigating
serum TK in other control groups (e.g. chronic diseases such
as chronic obstructive airways disease, congestive cardiac
failure and rheumatoid arthritis) would be of interest but is
beyond the scope of this preliminary report.
Serum TK levels in patients with primary operable breast
cancer were not related to prognosis as measured by the
Nottingham prognostic index for primary breast cancer
(Todd et al., 1987) (Table I).
The percentage of TKI and TK2 making up the total
serum TK was similar in all three prognostic groups as
indicated by similar % CTP/ATP TK activities (Table I).
Therefore while serum TK may be of diagnostic value in
primary operable disease, neither serum TK nor the relative
% TKI or % TK2 are of prognostic value at this stage of
disease.
In systemic disease our results suggest that both iso-
enzymes TKI and TK2 are elevated although the increase in
TKI activity appears slightly greater as indicated by the
cancer patients having lower % CTP/ATP TK activities than
controls. These results confirm a previous report by
McKenna and colleagues. Other malignancies have been
reported to be associated with greater increases in serum
TKI than in TK2, a finding in keeping with the observation
that TKI is associated with dividing cells (Bello, 1974). The
significance of elevation of both TKI and TK2 in breast
cancer is uncertain at present. However, Sakamoto and col-
leagues (1986) found both forms of TK to be elevated in
human mammary tumours, albeit with a greater relative
increase in TK1.
The source of the elevated serum TK is as yet uncertain. It
may be due to a combination of the release of TK due to
cancer cell death (such cells may not be dividing rapidly at
the time of death), leakage of TK from rapidly dividing
cancer cells (this would favour an increase in TK1 relative to
TK2) and release of TK from normal cell death as part of
tumour associated tissue destruction (this might have no
effect on the ratio of the two enzymes).
Serial serum samples during the disease-free interval of 20
primary operable patients in the poor prognostic group
showed that serum TK reflect rather than predicts recurrent
disease.
Pre-treatment TK activity did not predict which patients
with systemic disease would respond or progress (mean pre-
treatment TK value 9.1 and 8.6 respectively) on endocrine
therapy.
Changes in serum TK correctly reflected clinical response
in four out of five responders, with the remaining patient
being biochemically unassessable. In four out of five progres-
sors changes in serum TK correctly reflected clinical progres-
sion with the remaining patient having an elevated though
stable serum TK. Eight patients were therefore correctly
assessed using serum TK measurements, one patient was
biochemically unassessable and the remaining patient showed
a persistently elevated though stable marker rather than an
increasing serum TK level. Changes in serial TK above the
coefficient ofvariation occurred in four out offive responders
and progressors (Tables IV and V). Serum TK appears to be
a useful marker in monitoring therapy in patients with
systemic breast cancer.
It has been reported that cultures of rapidly proliferating
tumour cells release TK into the surrounding medium (Bris-
tow et al., 1988) and it is thought that TK is released from
tumour cells into the circulation (Kreis et al., 1982). Our
results showing an increase in serum TK activity in patients
with progressive disease would be consistent with this experi-
mental work. The correlation between serial serum TK levels
and response to therapy is an interesting finding and requires
confirmation with a larger number of patients.
Serum TK appears a potentially important marker in
systemic breast cancer in that TK values in patients with
systemic disease was significantly higher than in patients with
operable breast cancer, normal controls or patients with
acute inflammatory gastrointestinal diseases. Serial changes
in serum TK in patients with systemic disease reflect response
to endocrine therapy.
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